64th ASH Annual Meeting and Exposition: 705. Cellular Immunotherapies: Novel Predictors of Response or Toxicity to Cellular Therapies

Symposia: Cellular Immunotherapies: Late Phase and Commercially Available Therapies Oral and Poster Abstracts
Oral

Research, Biological therapies, artificial intelligence (AI), clinical trials, adult, Lymphomas, non-Hodgkin lymphoma, Translational Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Clinical Research, Diseases, immune mechanism, cell expansion, Therapies, aggressive lymphoma, Lymphoid Malignancies, Adverse Events, Biological Processes, Technology and Procedures, Study Population, profiling, Human, machine learning

La Nouvelle Orleans Ballroom AB (Ernest N. Morial Convention Center)

Moderators:

Christine L Phillips, MD, Cincinnati Children's Hospital Medical Center and Aimee C Talleur, MD, St. Jude Children's Research Hospital

Disclosures:

No relevant conflicts of interest to declare.

2:00 PM

259

Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7

Frederick L. Locke, MD¹, Olalekan O. Oluwole, MBBS², John Kuruvilla, MD³, Catherine Thieblemont, MD, PhD⁴, Franck Morschhauser, MD, PhD⁵^*, Gilles Salles, MD, PhD⁶, Steven P Rowe, MD, PhD⁷^*, Saran Vardhanabhuti, PhD⁸^*, Simone Filosto, PhD⁸^*, Christina To, MD⁸^*, Paul Cheng, MD, PhD⁸, Marco Schupp, MD⁸^*, Ronald Korn, MD, PhD⁹^* and Marie José Kersten, MD, PhD¹⁰

¹Moffitt Cancer Center, Tampa, FL
²Vanderbilt University Cancer Center, Nashville, TN
³Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
⁴Hemato-Oncology, DMU DHI, University of Paris, Hôpital Saint-Louis, Paris, France
⁵University of Lille, Centre Hospitalier Universitaire de Lille, Lille, France
⁶Memorial Sloan Kettering Cancer Center, New York, NY
⁷Johns Hopkins School of Medicine, Baltimore, MD
⁸Kite, a Gilead Company, Santa Monica, CA
⁹Imaging Endpoints, Scottsdale, AZ
¹⁰Amsterdam UMC, University of Amsterdam, on behalf of HOVON/LLPC, Amsterdam, Netherlands

2:15 PM

260

A 7-Gene Signature in Unmanipulated Leukaphereses Correlates with in-Vivo CAR T-Cell Expansion and Survival of Lymphoma Patients Receiving Tisagenlecleucel or Axicabtagene Ciloleucel Therapy

Cristiana Carniti¹^*, Nicole Caldarelli^1,2^*, Francesca Nanetti¹^*, Martina Magni¹^*, Emma Esposito³^*, Tommaso Torelli⁴^*, Luca Agnelli⁴^*, Silvia Brich⁵^*, Chiara Monfrini¹^*, Eugenio Fardella⁶^*, Paolo Longoni⁷^*, Daniele Lorenzini⁵^*, Martina Pennisi¹^*, Annalisa Chiappella¹^* and Paolo Corradini^1,8

¹Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
²Università degli Studi di Milano, Milano, Italy
³School of Medicine, Università degli Studi di Milano-Bicocca, Milano, Italy
⁴Department of Pathology and Department of Molecular Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
⁵Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
⁶School of Medicine, Università Degli Studi Di Milano, Milano, Italy
⁷Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy
⁸School of Medicine, Università degli Studi di Milano, Milano, Italy

2:30 PM

261

Durable Response to CD19 CAR T Cell Therapy Is Associated with Cytotoxicity and Clonotypic Expansion of the Native T Cell Repertoire

Giulia Cheloni, PhD¹^*, Dimitra Karagkouni, PhD^1,2^*, Yered Pita-Juarez, PhD^1,2^*, Daniela Torres¹^*, Eleni Kanata^1,2^*, Zachary M. Avigan, MD³, Jessica Liegel, MD¹, Dina Stroopinsky, PhD¹^*, Brodie Miles, PhD⁴^*, Gayatri Tiwari⁴^*, Jenny Kim, MD⁴^*, Mike Mattie, PhD⁴^*, Jacalyn Rosenblatt, MD¹, David Avigan, MD¹ and Ioannis Vlachos, PhD^1,2,5^*

¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
²Broad Institute of MIT and Harvard, Cambridge, MA
³Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
⁴Kite, a Gilead Company, Santa Monica, CA
⁵Spatial Technologies Unit, Harvard Medical School Initiative for RNA Medicine, Boston, MA

2:45 PM

262

Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel

Mark B. Leick, MD¹^*, Seunghun Han, BS²^*, Kathleen M.E. Gallagher, PhD¹^*, Harrison Silva³^*, Grace Martin¹^*, Sabrina Camp²^*, Hoyin Chu, BS⁴^*, Riaz Gillani, M.D.⁵^*, Michael C. Kann¹^*, Bryan D. Choi, MD, PhD¹^*, Rebecca Larson, PhD¹^*, Merle Phillips¹^*, Tamina Kienka¹^*, Stefanie R. Bailey, PhD¹^*, Charlotte Graham, MRCP, BSc, MBBS¹^*, Christopher R. Reilly, MD⁴^*, Max Jan, MD, PhD¹, Elba Gonzalez¹^*, Nora K. Horick, MS⁶^*, Justin Budka, PhD⁷^*, Simone Filosto, PhD⁷^*, Rhine R. Shen, PhD⁷^*, Eliezer Van Allen, MD⁴^*, Saud H AlDubayan, MD⁴^* and Marcela V. Maus, MD⁸

¹Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
²Broad Institute, Cambridge
³Cancer Center, Massachusetts General Hospital, Boston, MA
⁴Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Boston Children's Hospital, Boston, MA
⁶Biostatistics, Harvard Medical School, Boston, MA
⁷Kite, a Gilead Company, Santa Monica, CA
⁸Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Lexington, MA

3:00 PM

263

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

Sandeep Raj, MD¹, Miguel-Angel Perales, MD², Joshua A Fein, MD³, Ana Alarcon Tomas¹^*, Connie Lee Batlevi, MD, PhD⁴, Magdalena Corona De Lapuerta, MD⁵^*, Parastoo B Dahi, MD²^*, Ivetta Danylesko⁶^*, Shalev Fried, BSc⁷^*, Tyler Funnell, PhD⁸^*, Sergio A. Giralt, MD, FACP, FASTCT⁹^*, Elad Jacoby, MD¹⁰, Meirav Kedmi⁶^*, Richard J. Lin, MD², Arnon Nagler, MD¹¹, Karthik Nath, MBBS, PhD¹^*, Allison Parascondola, BA¹^*, M.Lia Palomba, MD¹², Gilles Salles, MD, PhD¹³, Michael Scordo, MD¹⁴, Gunjan L. Shah, MD¹⁵^*, Noga Shem-Tov, MD⁶^*, Avichai Shimoni, MD⁶^*, John Slingerland¹⁶^*, Moneeza Walji, MD, BSc, MPH¹, Ronit Yerushalmi, MD⁶, Abraham Avigdor, MD⁷, Marcel R M van den Brink, MD, PhD¹⁵ and Roni Shouval, MD, PhD²

¹Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
²Adult Bone Marrow Transplant Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
³Weill Cornell Medical College, New York, NY
⁴Lymphoma Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NEW YORK, NY
⁵Servicio de Hematología, Hospital 12 de Octubre, Madrid, Spain
⁶Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Ramat Gan, Israel
⁷Chaim Sheba Medical Center, Ramat Gan, Israel
⁸Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY
⁹Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰Pediatric Hematology and Oncology Department, The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel
¹¹Hematology and Bone Marrow Transplant Unit, Chaim Sheba Medical Center, Tel Hashomer, Israel
¹²Lymphoma Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹³Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁴Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center/New York, New York, NY
¹⁵Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁶Memorial Sloan Kettering Cancer Center, New York, NY

3:15 PM

264

The CAR-Hematotox Score Identifies Patients at High Risk for Hematological Toxicity, Infections and Poor Clinical Outcomes Following Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma

Kai Rejeski, MD¹, Yucai Wang, MD, PhD², Omar Albanyan, MD³, Javier L Munoz, MD, MBA⁴^*, Pierre Sesques, MD⁵^*, Gloria Iacoboni, MD⁶^*, Lucía López Corral, MD PhD⁷^*, Razan Mohty, MD³, Martin Dreyling, MD¹, Frederick L. Locke, MD³, Pere Barba, MD, PhD⁶^*, Emmanuel Bachy, MD, PhD⁵^*, Yi Lin, MD, PhD⁸, Marion Subklewe, MD⁹ and Michael D. Jain, MD, PhD¹⁰

¹Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
²Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
³Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁴Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ
⁵Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre Benite, France
⁶Department of Hematology, University Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
⁷Department of Hematology, Hospital Clínico Universitario de Salamanca (CAUSA/IBSAL), Salamanca, Spain
⁸Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
⁹Department of Medicine III (Hematology/Oncology), LMU University Hospital Munich, Muenchen, Germany
¹⁰Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

705.O2.6 705. Cellular Immunotherapies: Novel Predictors of Response or Toxicity to Cellular Therapies